Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Laure Charvet

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
World Journal of Urology|June 25, 2026
Bladder drainage using the coreflow prostatic stent after REZUM therapyThibaut Long-Depaquit, Frederica Sordelli, Anne Laure Charvet, et al.
World Journal of Urology|December 27, 2025
Radical prostatectomy outcomes in patients with PI-RADS 5 lesions and favorable prostate cancerAnne-Laure Charvet, Thibaut Long Depaquit, Hector Bened, et al.
World Journal of Urology|August 18, 2022
Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?Michael Baboudjian, Mathieu Roumiguié, Alexandre Peltier, et al.
World Journal of Urology|March 15, 2023
Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approachMichael Baboudjian, Alberto Breda, Thierry Roumeguère, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
World Journal of Urology|June 25, 2026
Bladder drainage using the coreflow prostatic stent after REZUM therapyThibaut Long-Depaquit, Frederica Sordelli, Anne Laure Charvet, et al.
World Journal of Urology|December 27, 2025
Radical prostatectomy outcomes in patients with PI-RADS 5 lesions and favorable prostate cancerAnne-Laure Charvet, Thibaut Long Depaquit, Hector Bened, et al.
World Journal of Urology|August 18, 2022
Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?Michael Baboudjian, Mathieu Roumiguié, Alexandre Peltier, et al.
World Journal of Urology|March 15, 2023
Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approachMichael Baboudjian, Alberto Breda, Thierry Roumeguère, et al.
Pageof 1